1. 300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. Issue 3 (September 2015) Authors: Rasco, D.W.; Middleton, M.R.; Gonzalez, R.; Corrie, P.; Pavlick, A.; Lorigan, P.; Plummer, R.; Gore, M.; Herbert, C.; Agarwala, S.S.; Logan, T.F.; Khleif, S.N.; Papadopoulos, K.P.; Rangachari, L.; Suri, A.; Xu, Q.; Kneissl, M.; Bozón, V.; Olszanski, A.J. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006. (February 2017) Authors: Long, G.V.; Robert, C.; Arance, A.; Blank, C.; Ribas, A.; Lorigan, P.; Mortier, L.; Schachter, J.; Middleton, M.R.; Neyns, B.; Sznol, M.; Zhou, H.; Ebbinghaus, S.; Ibrahim, N.; Steven, N. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Delayed oral toxicity from long‐term vemurafenib therapy. (1st May 2016) Authors: Lloyd‐Lavery, A.; Hodgson, T.; Coupe, N.; Bond, S.; Shah, K.; Espinosa, O.; Payne, M.J.; Middleton, M.R.; Matin, R.N. Journal: British journal of dermatology Issue: Volume 174:Number 5(2016) Page Start: 1159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Delayed oral toxicity from long‐term vemurafenib therapy. (30th March 2016) Authors: Lloyd‐Lavery, A.; Hodgson, T.; Coupe, N.; Bond, S.; Shah, K.; Espinosa, O.; Payne, M.J.; Middleton, M.R.; Matin, R.N. Journal: British journal of dermatology Issue: Volume 174:Number 5(2016) Page Start: 1159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. (1st April 2014) Authors: Sinha, R.; Lecamwasam, K.; Purshouse, K.; Reed, J.; Middleton, M.R.; Fearfield, L. Journal: British journal of dermatology Issue: Volume 170:Number 4(2014:Apr.) Page Start: 997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. (April 2014) Authors: Sinha, R.; Lecamwasam, K.; Purshouse, K.; Reed, J.; Middleton, M.R.; Fearfield, L. Journal: British journal of dermatology Issue: Volume 170:Number 4(2014:Apr.) Page Start: 997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. (1st January 2014) Authors: Lorigan, P.; Marples, M.; Harries, M.; Wagstaff, J.; Dalgleish, A.G.; Osborne, R.; Maraveyas, A.; Nicholson, S.; Davidson, N.; Wang, Q.; Pericleous, L.; Bapat, U.; Middleton, M.R. Journal: British journal of dermatology Issue: Volume 170:Number 1(2014:Jan.) Page Start: 87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. (January 2014) Authors: Lorigan, P.; Marples, M.; Harries, M.; Wagstaff, J.; Dalgleish, A.G.; Osborne, R.; Maraveyas, A.; Nicholson, S.; Davidson, N.; Wang, Q.; Pericleous, L.; Bapat, U.; Middleton, M.R. Journal: British journal of dermatology Issue: Volume 170:Number 1(2014:Jan.) Page Start: 87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗